Skip to main content

CleanCore Acquires Additional 100 Million DOGE, Expanding Digital Asset Treasury to Over 600 Million DOGE

Continues To Build Momentum Toward Achieving Target of 1 Billion DOGE Held Within 30 Days OMAHA, Neb., Sept. 16, 2025 (GLOBE NEWSWIRE) — CleanCore Solutions, Inc. (NYSE American: ZONE) (“CleanCore” or the “Company”), today announced that it has acquired an additional 100 million Dogecoin (“DOGE”), bringing the total holdings of its Official Dogecoin Treasury (the “Treasury”) to more than 600 million DOGE. The Treasury, backed by the Dogecoin Foundation and its corporate arm, House of Doge, continues to execute on the Company’s strategic accumulation plan, with a near-term objective of acquiring up to 1 billion DOGE within 30 days CleanCore’s long-term objective is to acquire up to 5% of Dogecoin’s circulating supply, strengthening its position as the central treasury for the Dogecoin ecosystem. As institutional and corporate treasuries...

Continue reading

Strata Acquires Keystone Perfusion, Creating Integrated Organ Recovery Platform, Diversifying into Other Medical Services

Keystone is expected to generate approximately $65 million of revenue and approximately $13 million of Adjusted EBITDA(1) in the full-year 2025, with revenue expected to grow more than 50% in 2025 versus 2024 Acquisition follows multi-year partnership between Strata and Keystone whereby Keystone has successfully recovered hundreds of organs on behalf of Strata customers $124 million acquisition represents an approximate 9x multiple of 2025 estimated Adjusted EBITDA(1); Keystone’s go forward Free Cash Flow(1) conversion is expected to be approximately 80%NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) — Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), formerly known as Blade Air Mobility, Inc. (Nasdaq: BLDE), today announced that it has completed the acquisition of Keystone Perfusion...

Continue reading

SERB Pharmaceuticals Completes Acquisition of Y-mAbs Therapeutics

West Conshohocken, PA, Sept. 16, 2025 (GLOBE NEWSWIRE) — SERB Pharmaceuticals (“SERB”), a global specialty pharmaceutical company focused on rare diseases and medical emergencies, today announced the successful completion of its acquisition of Y-mAbs Therapeutics, Inc. (“Y-mAbs”), a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer.  “We are excited to welcome Y-mAbs into SERB. The acquisition strengthens our Rare Oncology portfolio with the addition of Danyelza® (naxitamab-gqgk) and brings deep oncology expertise that will help us to expand our partnerships with the US oncology community and to advance treatments for rare and hard-to-treat cancers”, said Vanessa Wolfeler, Chief Executive Officer of SERB. “This marks a significant...

Continue reading

Premier American Uranium Completes Acquisition of Nuclear Fuels

TORONTO, Sept. 16, 2025 (GLOBE NEWSWIRE) — Premier American Uranium Inc. (“PUR” or “Premier American Uranium”) (TSXV: PUR, OTCQB: PAUIF) and Nuclear Fuels Inc. (“NF” or “Nuclear Fuels”) (CSE: NF, OTCQX: NFUNF) are pleased to announce the completion of the previously announced arrangement (the “Arrangement”) whereby Premier American Uranium has acquired all of the issued and outstanding common shares of Nuclear Fuels (the “NF Shares”). The Arrangement results in PUR acquiring 100% of the NF Shares and NF becoming a wholly owned subsidiary of PUR. Pursuant to the Arrangement, Nuclear Fuels shareholders (the “NF Shareholders”) received 0.33 of a common share of PUR (each whole share, a “PUR Share”) for each NF Share held. In aggregate, PUR issued 32,521,748 PUR Shares under the Arrangement. Colin Healey, CEO of PUR commented, “With...

Continue reading

Medicines360 acquires global rights to PeriPeach™, advancing new maternal health technology through the 360 Innovation Hub™

SAN FRANCISCO, Sept. 16, 2025 (GLOBE NEWSWIRE) — Medicines360, a women’s health innovation organization with a mission to be a catalyst for change, today announced that it has acquired global licensing rights to PeriPeach, an investigational medical device designed to prevent severe perineal tears during birth, from Fruits of Labor, Inc. PeriPeach will now advance through the 360 Innovation Hub, Medicines360’s platform for accelerating transformative women’s health solutions. PeriPeach is designed to address one of the most preventable maternal injuries in childbirth: obstetric anal sphincter injuries (OASIS), also known as severe perineal tears. During birth, the pelvic floor muscles stretch to three times their original size.i A majority of first-time mothers – up to 90% – experience tears during vaginal birth, with up...

Continue reading

Aspen Group, Inc. Announces Plan to Merge Aspen University and United States University

NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) — Aspen Group, Inc. (“AGI”) (OTCQB: ASPU), an education technology holding company and the parent company of Aspen University (AU) and United States University (USU), announced today the commencement of the merger process between AU and USU, with USU as the surviving entity. This merger is a strategic move to enhance the company’s long-term sustainability by uniting the unique strengths and rich legacies of both institutions. By merging the two school’s resources, faculty, and academic programs, the company will be able to offer students a wider array of courses, new research opportunities, and expanded career pathways. The Board of Trustees of both AU and USU have approved the merger. The institutions are required to obtain regulatory confirmation and/or approval for this merger,...

Continue reading

Form 8.3 – [TREATT PLC – 15 09 2025] – (CGAML)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree TREATT PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position...

Continue reading

Form 8.3 – [IQE PLC – 15 09 2025] – (CGAML)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree IQE PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

HALO Dream Inc. Acquires Child Craft, Expanding Its Premium Nursery Portfolio

Third acquisition in 16 months extends HALO’s leadership from premium sleepwear to nursery decor LOS ANGELES and NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) — HALO Dream Inc. (“HALO”), a portfolio company of Transom Capital Group (“Transom”), is proud to announce the acquisition of Child Craft, a beloved and iconic brand known for its high-quality wood nursery furniture and decor. Child Craft’s products include cribs, beds, dressers and other essentials that have earned the trust of American families for generations. This acquisition marks HALO’s third in just 16 months, following the successful integrations of BreathableBaby (May 2024) and Baby Merlin (March 2025). Together, these acquisitions reinforce HALO’s commitment to delivering premium juvenile sleep solutions that help babies—and their parents—sleep better and longer. The...

Continue reading

Zen Media Acquires Optimum7, Creating the First AI-Native, Outcome-Driven Growth Agency

Strategic merger unites AI-powered PR, performance marketing, SEO, and RevOps under one scalable, productized platform LAS VEGAS and MIAMI, Sept. 16, 2025 (GLOBE NEWSWIRE) — Zen Media, a modern day top pr agency, today announced the acquisition of Optimum7, a top e-commerce and Shopify performance firm, in a $10 million deal. The combined company establishes the first AI-native, outcome-driven growth agency, unifying brand visibility, performance marketing, and revenue operations into one integrated system. With this acquisition, Zen Media moves beyond the traditional agency model to offer a full-funnel growth architecture purpose-built for the AI era. This productized framework is designed for speed, transparency, and scalability, helping brands move from awareness to measurable outcomes with clarity. Leadership RealignmentDuran...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.